LENZ Therapeutics (LENZ) Total Liabilities (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Total Liabilities data on file, last reported at $26.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $26.0 million, up 181.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.0 million (up 181.79% YoY), and the FY2025 annual result was $21.5 million, up 91.95% from the prior year.
• Total Liabilities rose to $26.0 million in Q1 2026 per LENZ's latest filing, from $21.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $62.9 million in Q2 2023 and troughed at $8.7 million in Q3 2024.
• A 5-year average of $22.9 million and a median of $18.4 million in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities soared 310.29% in 2023, then sank 85.97% in 2024.
• A 5-year view of Total Liabilities shows it stood at $25.6 million in 2022, then retreated by 23.09% to $19.7 million in 2023, then plunged by 43.04% to $11.2 million in 2024, then soared by 91.95% to $21.5 million in 2025, then increased by 20.92% to $26.0 million in 2026.
• Business Quant data shows LENZ's Total Liabilities at $26.0 million in Q1 2026, $21.5 million in Q4 2025, and $16.8 million in Q3 2025.